KOD Company Profile and Key Details

Kodiak Sciences Inc. (NASDAQ:KOD) closed at $27.30 USD, gaining $1.30 (5.00%) from the previous close of $26.00. The stock is currently mid-range between its 52-week high and low $1.92 and $28.85. With a market capitalization of about $1.44 billion, Kodiak Sciences Inc. is classified as a small-cap and shows higher-than-market volatility (beta ~2.69). Key stats such as the average daily volume over the past year has been around 946.66 thousand shares, volume is running light vs its 52-week average. Headquartered in Palo Alto, CA, Kodiak Sciences Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Victor Perlroth, the company employs approximately 109 people and listed since October 04, 2018. Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases.

KOD has shown sold momentum, gaining 7.75% over the past week and 172.82% over the past quarter, though year-to-date performance is up 161.31%. Short-term trend indicators are bearishly aligned (SMA20 8.96%, SMA50 29.0%, SMA200 168.48%). The stock’s 14-day RSI is 62.98 (firm momentum), while the ATR of 2.12 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -9.69% below its high and over 1254.17% above its low. Average 10-day trading volume of 1.47 million shares is slightly above the 3-month average of 1.01 million, indicating heightened recent market interest.

Kodiak Sciences Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.86. This means the shares are trading above this model’s fair value.

Kodiak Sciences Inc. has 52.82 million shares outstanding. The public float is 32.42 million shares, elevated short interest at 7.74% of float. This equals 2.52 million shares. The short ratio is 4.26 days. Institutional investors hold 83.86% of the float. Insiders own 5.52%. BAKER FELIX holds 15.62 million shares, PERLROTH VICTOR has 2.17 million shares and BAKER BROS. ADVISORS LP has 1.56 million shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Kodiak Sciences Inc. generated EPS of -$4.12 over the past year. Five-year average earnings growth is -21.78%. Wall Street analysts project EPS growth of 1.89% annually over the next five years. The latest quarter delivered EPS of -$1.16. The next quarter is forecast at -$1.01. Next year's EPS is expected at $39.53. Analyst sentiment is neutral. Analyst rating data shows there are 2 Strong Buy ratings, 3 Buy ratings, 6 Hold ratings, 0 Sell rating and 1 Strong Sell ratings. Price targets range from $40.00 to $3.00. The high target offers 53.85% upside. The low target suggests -88.46% downside. The mean target is $17.00. This offers -34.62% upside. Kodiak Sciences Inc. earnings surprise history is a mixed track record. The quarter that ended November 13, 2025, missed forecasts by 8.41%. The prior quarter beat by 1.98%. Over the last six quarters, Apple has recorded several small beats. These include -1.15% in August 14, 2024.

Kodiak Sciences Inc. (NASDAQ:KOD) shares are up 161.31% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Kodiak Sciences Inc. trading at a premium to the broader market with a P/E of -8.82. Analyst sentiment is mixed, with the majority of ratings in Neutral territory and a mean price target of $52.10, suggesting 100.38% upside. Our AI forecast model points to short-term strength (9.08% over two weeks), a medium-term fall (-24.85% over three months), and a longer-term gain (6.46% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Kodiak Sciences Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 9.08%, with price expected at $28.36 by January 02, 2026, within a range of $26.84 to $29.79 3-Month Outlook: Projected fall of -24.85%, reaching $19.54 by March 19, 2026, with a range of $19.26 to $19.72. 1-Year Outlook: Projected gain of 6.46%, with price at $27.68 by December 18, 2026, within a range of $25.99 to $29.02.

Kodiak Sciences Inc. trades at a P/E ratio of -8.82, slightly below the S&P 500 average, with a price-to-sales ratio of 51.63 and a price-to-book ratio of 58.01 reflecting a rich premium to book value. The P/FCF stands at -10.81, also below market averages. Compared to sector medians, Kodiak Sciences Inc. P/S is trading rich, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.